A Clinical trial to evaluate the efficacy of Siddha drugs Gandhaga Rasayanam (Internal) & Navanatha sittha thailam (External) in patients having multiple joint pain

An open pilot study on Uthiravatha suronitham (Rheumatoid arthitis) with the trial drug Gandhaga rasayanam (Internal) and Navanatha sittha thailam (Ext)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/05/008469

Enrollment

Registered

2017-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having arthritis of three or more joints , Patients having RA factor POSITIVE , morning stiffness, CRP positive and anemia.

Interventions

Intervention1: GANDHAGARASAYANAM(INT) NAVANATHASIDDHA THAILAM(EXT): Nil Intervention2: Gandhaga rasayanam (int): Gandhaga rasanayam (int)_500mg twice daily with hot water for 48 days Intervention3: Na

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having arthritis of 3 or more joints 2. Morning stiffness 3. RA factor positive 4. C-Reactive Protein (CRP) positive 5. Anti Cyclic Citrullinated Peptide (Anti CCP) Positive 5. Patients who are willing to undergo laboratory investigations

Exclusion criteria

Exclusion criteria: 1. Rheumatic fever 2. History of sulphur allergy 3. Psoriatic arthropathica, 4. Progressive systemic sclerosis 5. Gouty arthritis, 6. Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Reduction in pain and swelling and morning stiffnessTimepoint: 12months	—

Secondary

Measure	Time frame
To study the safety parameters of the drug before and after treatmentTimepoint: 12months	—

Countries

India

Contacts

Public ContactDr M Mohamed mustafa

Govt siddha medical college

drshrisaranya@gmail.com8098372738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026